Fin Cascade

Prices as of 8 Oct 2026 close · Not investment advice

Metropolis Healthcare Limited

NSE: METROPOLISHealthcare Service Provider

Share price

₹529.25

+0.65% close of 9 Oct 2026

Market cap ₹10,909 CrP/E 51.6 (as of 8 Oct 2026)

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

68

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹10,909 Cr

P/E ratio

51.6

P/B ratio

7.2

ROCE

17.8%

ROE

13.6%

Dividend yield

0.4%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹602.1052-week low ₹421.75

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 21.8% over the past year, and 10.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 26.1% to 24.7% over the last four years.

Whether it grew faster than its sector

It grew 10.0% a year against a sector median of 13.1% — 3.1 percentage points slower.

Room to re-rate, or risk of de-rating

At 51.6× earnings it costs 2.2× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 56.7×, across 5 companies. It is against its own five-year median of 57.6×, the 29th percentile of its own range.

Whether growth justifies the valuation

Priced at 4.7 times its growth rate, on earnings growth of 11%.

Profit growthPrice per ₹1 profitPer 1% growth
Metropolis Healthcare Limited — this one11%/yr51.6×₹4.7
Dr. Lal Path Labs Ltd.30%/yr56.7×₹1.9
Vijaya Diagnostic Centre Limited24%/yr76.5×₹3.2
Thyrocare Technologies Limited36%/yr44.3×₹1.2
Nephrocare Health Services Limited103%/yr73.7×—
Krsnaa Diagnostics Limited18%/yr17.5×₹0.97

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 8 of 12 on returns, 11 of 11 on growth, 9 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 17.8% on capital, ahead of 33% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1378 crore of cash from the business, spent ₹264 crore on plant and equipment, and returned ₹512 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 141 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being paid 26 days before it paid its own suppliers to paid 15 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

9 of 9 checks clear · 100%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew about 17% and profit margin reached 25.2%, ahead of the growth and margin-improvement run rate management had set.

Announced 4 Aug 2026 · Consolidated · Unaudited

Revenue

₹450 Cr

Revenue vs last year

+16.6%

Revenue vs last quarter

+5.9%

Net profit

₹57 Cr

Profit vs last year

+26.4%

Profit vs last quarter

+11.5%

Net margin

12.6%

EPS

₹2.73

Earnings call transcript · 5 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹10,909 Cr
Prev close
₹529.25
52w High
₹609
52w Low
₹412
Enterprise value
₹10,809 Cr
Beta
0.6
Price CAGR 1y
7.0%
Price CAGR 3y
13.0%
Price CAGR 5y
-5.0%
Price CAGR 10y
—

Ratios

Return on assets
9.0%
PEG ratio
4.8
P/E ratio
51.6
P/B ratio
7.2
EV / EBITDA
25.6
Industry P/E
44.1
ROCE
17.8%
ROCE 5y average
19.0%
ROE
13.6%
Debt / Equity
0.2
Interest coverage
9.9
Dividend yield
0.4%
ROE 3y average
12.0%
ROE last year
14.0%

Annual P&L

Annual revenue
₹1,646 Cr
Annual profit
₹191 Cr
Operating margin
25.0%
Net profit margin
11.6%
EBITDA margin
24.7%
Sales growth 3y
12.8%
Sales growth 5y
10.5%
Profit growth 3y
11.0%
Profit growth 5y
1.0%
EPS
₹9.2
Sales growth TTM
22.0%
Profit growth TTM
37.0%
Dividend payout
55.0%

Quarter P&L

Sales latest quarter
₹450 Cr
Profit latest quarter
₹57 Cr
YoY quarterly sales growth
16.6%
YoY quarterly profit growth
26.7%
OPM latest quarter
24.7%

Balance Sheet

Book Value
₹73.8
Face Value
₹2.0
Total debt
₹232 Cr
Total cash
₹62 Cr
Borrowings
₹232 Cr
Reserves / Equity
35.9

Cash Flow

Operating cash flow
₹351 Cr
Free cash flow
₹300 Cr
FCF yield
2.5%
Net cash flow
₹15 Cr

Shareholding

Promoter holding
48.9%
FII holding
11.0%
DII holding
35.1%
Public holding
5.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Dr Lal Pathlabs1,915.0057.132,1430.73170.528.0797.719.128.0
Vijaya Diagnost.1,440.6079.214,8380.1453.137.6231.022.820.5
Metropolis Healt533.0053.111,0570.3756.925.8450.216.617.8
Thyrocare Tech.504.2544.48,0261.8251.334.1240.024.335.4
Nephrocare Health Services625.3573.96,2880.0032.034.9281.823.715.3
Krsnaa Diagnost.535.8517.61,7380.3715.8-19.1210.719.912.7
Suraksha Diagno.312.7545.51,6290.1612.938.487.720.817.3
Median319.9532.51,1240.0011.028.095.219.120.5

Competes with: 3B Blackbio Dx Limited, Dr. Lal Path Labs Ltd., Gaudium IVF and Women Health Limited, Health X Platform Limited, Krsnaa Diagnostics Limited, Molbio Diagnostics Limited, Nephrocare Health Services Limited, One Global Service Provider Limited, Pramodini Medicare Limited, Sastasundar Ventures Limited, Suraksha Diagnostic Limited, Thyrocare Technologies Limited, Vijaya Diagnostic Centre Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales277309291331313350323345386429406425450
Expenses214234226251235260251283296321311317339
Material Cost727988797887
Change in Inventories000000
Purchases of Stock-in-Trade000000
Employee Cost8292959495107
Other Expenses129125138138143145
Operating Profit63756580799072629010895108111
OPM %23242224252622182325232525
Other Income3123233781-085
Exceptional items (within Other Income)000-9.100.110
Interest6656555556686
Depreciation21222526262728293132323932
Profit before tax39483751516142366171577078
Tax %26262628252426192626262727
Net Profit29362737384731294553425157
EPS in Rs1.411.731.331.781.852.271.531.412.172.5422.462.73
Diluted EPS in Rs5.668.66107.942.462.73

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4564755456477618569981,2281,1481,2081,3311,6461,710
Expenses3393594054675596197088808559201,0231,2401,288
Material Cost269325
Change in Inventories00
Purchases of Stock-in-Trade00
Employee Cost314377
Other Expenses446543
Operating Profit117116140181203237290348293288308406422
OPM %26242628272829282624232525
Other Income7293968-171234159151614
Exceptional items (within Other Income)0-8.99
Interest222441312253228242926
Depreciation21171719203946638994109134135
Profit before tax101128160164187169244293188175191259276
Tax %333633323424252724262426
Net Profit6882107112124128183215143128146191203
EPS in Rs152027275.996.298.95106.986.2479.179.73
Diluted EPS in Rs289.19
Dividend Payout %0100490553222192916055

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
13%
5 years
11%
3 years
13%
TTM
22%

Compounded profit growth

10 years
11%
5 years
1%
3 years
11%
TTM
37%

Stock price CAGR

10 years
—
5 years
-5%
3 years
13%
1 year
7%

Return on equity

10 years
19%
5 years
15%
3 years
12%
Last year
14%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital101010101010101010101041
Reserves3522693144054085136968769781,0861,3211,472
Borrowings145111867112379266197204232
Other Liabilities87107188110113160181256240254324386
Minority Interest3.6711
Total Liabilities4623915125265507501,0001,5211,4951,5471,8592,131
Fixed Assets1531422022072132963431,0591,1211,1771,4471,601
CWIP0110630620000
Investments16810114210233141016155571142
Other Assets141147167216298437647440340316341387
Total Assets4623915125265507501,0001,5211,4951,5471,8672,138

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity699110210490215249253247264263351
Cash from Investing Activity-5696-86136-10463-73648-89-199-220
Cash from Financing Activity-9-174-17-87-118-55-33163-292-181-87-115
Net Cash Flow414-118856279-3213-6-2315
Free Cash Flow4679459067179221223195200196300

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days575454576655454039384138
Inventory Days524638535544596864586551
Days Payable9296978890152160136136150171146
Cash Conversion Cycle173-52130-54-56-29-33-53-65-57
Working Capital Days328-2728332-9-26-22-16-18-15
ROCE %283446434340362917161518

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters505050504949494949494949
FIIs242219181917151313121011
DIIs172125272830303233353635
Public9.107.876.574.693.983.865.515.875.484.694.925
No. of Shareholders86,24979,87868,28358,10851,85248,57249,29350,01547,84646,67049,17550,636

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +6.2% (₹498.20 → ₹529.25)Brick size ₹19.01 (fixed)Bricks 20
₹450₹500₹550₹600₹529Jan '26Apr '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹529.25 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

29.35inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

30,45,209inr

2026-03-31

volume growth %

11.00pct

2026-06-30

News

News and filings about Metropolis Healthcare Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Healthcare Service Provider
Classification
Healthcare › Healthcare Service Provider
ISIN
INE112L01020

News impact

Big market events that reach Metropolis Healthcare Limited, and how the effect spreads.

24 Sept, 11:36 IST · Market event · high impact

Nephrocare shares tumble 5% | What’s driving the decline?

Large holders are selling about Rs 650 crore of kidney-care firm Nephrocare at a 5% discount, hurting current shareholders short-term while letting new buyers enter cheaper.

Healthcare

Who it hits first

  • Nephrocare Health Services, which runs kidney dialysis clinics, fell over 5% after reports that large holders want to sell about Rs 650 crore of shares at Rs 705 each.
  • That Rs 705 price is about 5% below the last close of Rs 741.90, so the market is repricing toward the cheaper deal price.
  • The business itself is unchanged — only the shareholding is shifting.

Who may gain

  • Buyers who get the block at Rs 705 gain an instant 5% discount to the Rs 741.90 close.
  • Patient investors who wanted Nephrocare shares can now buy the dip if the fall overdoes the discount.

Along the supply chain

Downstream

No direct downstream impact — hospitals it serves, including Max Healthcare, Fortis Healthcare, and Medanta, see no change to orders or contracts from this share sale.

Upstream

No direct supply-chain link upstream — Nephrocare lists no suppliers in the pack, and a shareholder sale does not change what it buys.

Where demand moves

Business

No change to patient visits, dialysis sessions, or clinic revenue — the Rs 650 crore sale moves existing shares between investors, not customers.

Capital

About Rs 650 crore of new share supply near Rs 705 pulls the price down short-term as traders sell; bargain hunters absorbing the block provide the offsetting buy flow.

How it spreads across sectors

Healthcare

No sector-wide impact — a single-company share sale with no change to hospital or lab demand; peers should trade flat.

When it plays out

Immediate

1–7 days: Nephrocare trades heavy near Rs 705 as the Rs 650 crore block clears; peers flat.

Medium term

1–6 months: price follows clinic results again, not the block; no lasting sector effect.

Short term

1–4 weeks: discount overhang fades if buyers hold; price stabilises unless more selling appears.

Who it hits first

  • Krsnaa Diagnostics won a 15-year Punjab government deal to run PET-CT cancer-imaging scans, opening a costly high-value scan business it did not have before.
  • The stock jumped 11% as investors priced in years of steady scan income from the long contract.

Who may gain

  • Krsnaa Diagnostics gains a 15-year revenue stream and a new high-value PET-CT line; no listed peer shares the award.

Along the supply chain

Downstream

Punjab government hospitals and patients get advanced cancer imaging locally instead of referring cases out.

Upstream

PET-CT scanners come from unlisted global makers (Siemens, GE, Philips) and tracer supply has no listed pure-play, so no listed upstream impact.

Where demand moves

Business

Punjab's public hospitals will send PET-CT scan demand to Krsnaa's new centres for 15 years; scanner makers and tracer suppliers are unlisted so no listed upstream benefit.

Capital

Money rotates into KRSNAA shares on the repricing; no sector-wide rotation since the award is exclusive to one company.

How it spreads across sectors

Healthcare

Mild positive: validates the PPP route for high-end diagnostics and hints other states may tender similar PET-CT deals.

When it plays out

Immediate

Shares already up 11%; follow-through depends on disclosed order value and rollout plan.

Medium term

Scan volumes and revenue/margin contribution from PET-CT over 1-6 months and beyond.

Short term

Agreement signing, centre commissioning schedule, and management commentary in quarterly results.

Who it hits first

  • AIOCD shutdown disrupts physical pharmacy access
  • E-pharmacies face regulatory scrutiny pressure
  • MEDPLUS in regulatory crossfire
  • APOLLOHOSP in-house pharmacy may gain refill volumes

Who may gain

  • Organized chemists if discount caps imposed
  • Pharma manufacturers if MRP enforcement strengthens
  • Hospital chains with in-house pharmacy

Along the supply chain

Downstream

Patient access disruption; chronic-care risk; insurance claims may rise

Upstream

Pharma manufacturers (Sun, Cipla, Lupin) — insulated as MRP intact

Where demand moves

Business

Physical pharmacy shutdown shifts volumes to e-pharm short-term. Longer-term regulatory caps reverse flow to organized retail.

Capital

Sector uncertainty discount. Capital prefers manufacturer-led pharma.

How it spreads across sectors

Consumer Services

E-pharm growth slowdown if caps imposed

Healthcare

Patient access risk

Pharma Retail

Regulatory uncertainty premium

codex additions

When it plays out

Immediate

MEDPLUS flat-to-negative (pledge); APOLLOHOSP flat

Medium term

Regulatory caps reshape pharma retail margins

Short term

NPPA/CDSCO commentary critical

Other sectors it reaches

  • {"causal_chain":"E-pharmacy order volumes and store shutdown disruption affect medicine fulfillment, hyperlocal delivery density, cold-chain handling, and reverse logistics demand.","direction":"mixed","example_tickers":["DELHIVERY","TCIEXP","VRLLOG"],"magnitude":"medium","notes":"Negative if regulatory pressure reduces e-pharmacy growth; positive short-term if consumers shift to online during physical-store shutdowns.","sector":"Logistics \u0026 Last-Mile Delivery","time_horizon":"immediate"}
  • {"causal_chain":"Any shift from offline pharmacy cash/card purchases to app-based medicine ordering increases UPI/card/wallet payment flows; discount caps could slow e-pharmacy transaction growth later.","direction":"mixed","example_tickers":["PAYTM","POLICYBZR","INFIBEAM"],"magnitude":"small","notes":"Listed pure-play exposure is limited; impact is more volume-sentiment than earnings material.","sector":"Digital Payments \u0026 Fintech","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"E-pharmacy apps often cross-sell diagnostics, subscriptions, and chronic-care packages; regulatory pressure on their core pharmacy funnel can affect lead generation for diagnostics.","direction":"negative","example_tickers":["LALPATHLAB","METROPOLIS","VIJAYA"],"magnitude":"small","notes":"Most listed diagnostics firms are not dependent on e-pharmacy, but digital acquisition partnerships could be affected.","sector":"Diagnostics \u0026 Preventive Health Platforms","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Patient access disruption at retail chemists may divert some medicine purchases and refills to hospital pharmacies, while Apollo faces scrutiny because it operates both hospital and pharmacy channels.","direction":"mixed","example_tickers":["APOLLOHOSP","MAXHEALTH","FORTIS"],"magnitude":"small","notes":"Potential footfall benefit for hospital pharmacies, offset by headline/regulatory risk for integrated players.","sector":"Hospital Chains With Outpatient Pharmacy/Diagnostics","time_horizon":"immediate"}
  • {"causal_chain":"Medicine affordability and chronic prescription adherence are relevant for claims experience; discount caps may raise patient out-of-pocket costs, while shutdowns can disrupt medicine access.","direction":"negative","example_tickers":["STARHEALTH","NIACL","ICICIGI"],"magnitude":"small","notes":"Likely indirect and slow-moving; more relevant if policy action materially raises recurring medicine costs.","sector":"Insurance \u0026 Health Benefit Platforms","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Regulatory pressure on e-pharmacies can increase demand for compliance systems, prescription validation, inventory traceability, and digital audit infrastructure across pharmacy networks.","direction":"positive","example_tickers":["TCS","INFY","LTIM"],"magnitude":"small","notes":"Large IT firms have diversified revenue, so stock impact is modest, but compliance-tech spending could rise.","sector":"IT Services / Healthtech Implementation","time_horizon":"1_to_6_months"}
  • {"causal_chain":"Pharmacies also sell OTC, nutraceutical, personal care, and wellness products; shutdowns disrupt channel sales, while discount regulation may alter online-offline channel economics.","direction":"mixed","example_tickers":["HINDUNILVR","DABUR","MARICO"],"magnitude":"small","notes":"Impact is limited because these companies have broad distribution beyond chemists.","sector":"FMCG / OTC Wellness Distribution","time_horizon":"1_to_4_weeks"}
  • {"causal_chain":"If regulators curb e-pharmacy discounts, organized offline pharmacy formats and neighborhood chemists gain durability, supporting pharmacy store economics and retail occupancy demand.","direction":"positive","example_tickers":["PHOENIXLTD","BRIGADE","PRESTIGE"],"magnitude":"small","notes":"Second-order effect; strongest only if offline retail economics structurally improve.","sector":"Commercial Real Estate / Retail Leasing","time_horizon":"1_to_6_months"}
  • {"causal_chain":"E-pharmacy apps rely on mobile ordering, digital prescriptions, and customer engagement; any accelerated online migration during shutdowns increases app traffic, while future discount caps could reduce engagement intensity.","direction":"mixed","example_tickers":["BHARTIARTL","IDEA","INDUSTOWER"],"magnitude":"small","notes":"Causal link exists but earnings sensitivity is negligible for large telecom names.","sector":"Telecom \u0026 Data Consumption","time_horizon":"immediate"}

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

19 May 2026interim₹1
20 Mar 2026bonus₹0
11 Nov 2025interim₹4
17 Nov 2023interim₹4
23 Feb 2023interim₹8
21 Feb 2022interim₹8
17 Feb 2021interim₹8
13 Feb 2020interim₹8

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 1, insert 6), 2020-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2020

Bulk & block deals

DateWhoBought / soldSharesPrice
11 Aug 2026METZ ADVISORY LLPSELL10,50,000₹564.00
11 Aug 2026DURU SHAH FAMILY TRUSTSELL10,50,000₹564.00
11 Aug 2026ADITYA BIRLA SUN LIFE MUTUAL FUNDBUY10,49,000₹564.00

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
13 Aug 2026Metz Advisory LLP · PromoterSELL10,50,00059.22
13 Aug 2026Duru Shah Family Trust · Promoter GroupSELL10,50,00059.22

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.